Recent studies have revealed a specialized population of ‘exhausted’ CD8+ T cells that expands on immune checkpoint blockade therapy for cancer and may explain how T cell responses are maintained in chronic conditions. Here, the authors describe their phenotypic, developmental and functional characteristics and why they should be harnessed for successful immunotherapy.
- Axel Kallies
- Dietmar Zehn
- Daniel T. Utzschneider